MX2013015128A - Epitopo y su uso en el antigeno de superficie del virus de la hepatitis b. - Google Patents

Epitopo y su uso en el antigeno de superficie del virus de la hepatitis b.

Info

Publication number
MX2013015128A
MX2013015128A MX2013015128A MX2013015128A MX2013015128A MX 2013015128 A MX2013015128 A MX 2013015128A MX 2013015128 A MX2013015128 A MX 2013015128A MX 2013015128 A MX2013015128 A MX 2013015128A MX 2013015128 A MX2013015128 A MX 2013015128A
Authority
MX
Mexico
Prior art keywords
epitope
hepatitis
surface antigen
hbv
virus surface
Prior art date
Application number
MX2013015128A
Other languages
English (en)
Other versions
MX347638B (es
Inventor
Se-Ho Kim
Kwang-Won Hong
Yong-Won Shin
Ki Hwan Chang
Min-Soo Kim
Jung-Ae Im
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2013015128A publication Critical patent/MX2013015128A/es
Publication of MX347638B publication Critical patent/MX347638B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un epítopo específico para el virus de la Hepatitis B (HBV) y uso del mismo. El epítopo descrito se encuentra en una posición conservadora en la que no ocurre mutagénesis y, por lo tanto, una composición incluye un anticuerpo para el epítopo anterior o una composición de vacuna que incluye el epítopo que tiene muy baja posibilidad de provocar degradación de la eficacia de curación debida a mutación de HSV, por lo tanto, es muy útil para el tratamiento de HBV.
MX2013015128A 2011-06-30 2011-07-25 Epitopo y su uso en el antigeno de superficie del virus de la hepatitis b. MX347638B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110064671A KR101281098B1 (ko) 2011-06-30 2011-06-30 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
PCT/KR2011/005477 WO2013002449A1 (en) 2011-06-30 2011-07-25 Epitope and its use of hepatitis b virus surface antigen

Publications (2)

Publication Number Publication Date
MX2013015128A true MX2013015128A (es) 2014-03-31
MX347638B MX347638B (es) 2017-05-05

Family

ID=47424324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015128A MX347638B (es) 2011-06-30 2011-07-25 Epitopo y su uso en el antigeno de superficie del virus de la hepatitis b.

Country Status (12)

Country Link
US (2) US9415100B2 (es)
EP (1) EP2726499B1 (es)
JP (1) JP5977346B2 (es)
KR (1) KR101281098B1 (es)
CN (1) CN103619870B (es)
BR (1) BR112013033129B1 (es)
CA (1) CA2839668C (es)
MX (1) MX347638B (es)
MY (1) MY163742A (es)
PH (1) PH12013502641A1 (es)
RU (1) RU2585525C2 (es)
WO (1) WO2013002449A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714284B2 (en) 2013-07-16 2017-07-25 National Health Research Institutes Antibodies and method for determining deletions in HBV pre-S2 region
WO2016085284A1 (ko) * 2014-11-28 2016-06-02 (주)셀트리온 B형 간염 바이러스 표면 항원의 에피토프 및 이에 특이적으로 결합하는 b형 간염 바이러스 중화 결합 분자
CN108271358A (zh) * 2014-12-10 2018-07-10 财团法人卫生研究院 判定HBV病毒pre-S2区域内缺失的抗体与其方法
WO2017026241A1 (ja) * 2015-08-07 2017-02-16 国立大学法人愛媛大学 質量分析を用いたｂ型肝炎ウイルスの測定方法
PL3402888T3 (pl) * 2016-01-12 2021-04-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Środki i sposoby leczenia hbv
CN113480641B (zh) * 2017-04-07 2023-04-11 厦门大学 用于治疗乙肝感染及相关疾病的抗体
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
CN118878648A (zh) * 2024-07-15 2024-11-01 大连理工大学 一种基因工程乙肝疫苗及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100246127B1 (ko) * 1997-07-02 2000-03-15 박호군 비형 간염 바이러스의 표면항원 프리-에스1에 대한 생쥐 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 그의 제조방법
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
JP2002525289A (ja) * 1998-09-01 2002-08-13 イノジェネティックス・ナムローゼ・フェンノートシャップ アネキシンに結合するベンゾジアゼピンおよびベンゾチアゼピン誘導体ならびにｈｓｂｓａｇペプチド、それらの組成物ならびに使用
AUPP706098A0 (en) * 1998-11-11 1998-12-03 North Western Health Care Network Biological compositions, components thereof and uses therefor
US6921534B2 (en) * 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US7485312B2 (en) * 2003-06-20 2009-02-03 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
AR046960A1 (es) * 2003-12-17 2006-01-04 Wyeth Corp Metodos para producir los conjugados portadores de peptidos inmunogenicos
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
US9052320B2 (en) * 2006-10-30 2015-06-09 Advanced Life Science Institute, Inc. Method for analysis of hepatitis B virus s antigen
KR101072895B1 (ko) 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체

Also Published As

Publication number Publication date
US9415100B2 (en) 2016-08-16
BR112013033129B1 (pt) 2022-05-03
CN103619870B (zh) 2016-09-21
JP5977346B2 (ja) 2016-08-24
CA2839668A1 (en) 2013-01-03
EP2726499A1 (en) 2014-05-07
KR20130003362A (ko) 2013-01-09
PH12013502641A1 (en) 2014-02-10
KR101281098B1 (ko) 2013-07-02
MX347638B (es) 2017-05-05
JP2014526885A (ja) 2014-10-09
MY163742A (en) 2017-10-31
RU2585525C2 (ru) 2016-05-27
RU2014102957A (ru) 2015-08-10
BR112013033129A2 (pt) 2017-12-12
US20140112923A1 (en) 2014-04-24
WO2013002449A1 (en) 2013-01-03
EP2726499A4 (en) 2015-03-04
EP2726499B1 (en) 2017-11-15
US20160311862A1 (en) 2016-10-27
CN103619870A (zh) 2014-03-05
CA2839668C (en) 2021-06-01

Similar Documents

Publication Publication Date Title
MY163742A (en) Epitope and its use of hepatitis b virus surface antigen
PH12017500727A1 (en) Modified virus-like particles of cmv
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2018004127A (es) Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos.
SA515360198B1 (ar) لقاحات غمس الوحدات الفرعية للسمك
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
EA201300915A1 (ru) Новый европейский штамм prrsv
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
PH12016501968A1 (en) Novel macrocyclic compounds
HRP20190393T1 (hr) Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12017500627A1 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
PH12020500414A1 (en) Method for producing influenza ha split vaccine
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
EP3225628A4 (en) Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus
MX385188B (es) Vacuna de rinitis equina.
WO2016012406A3 (en) Attenuated strain of prrs and potential use in immunising preparations
MX2014001158A (es) Virus recombinantes de influenza porcina y usos del mismo.
EP3545973A4 (en) COMPOSITION OF VACCINE CONTAINING PARTICLES OF THE HEPATITIS B VIRUS TYPE USED AS AN ADJUVANT
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).
UA116762C2 (uk) Рекомбінантний лектин омели білої та його застосування як ад'юванту

Legal Events

Date Code Title Description
FG Grant or registration